Navigation Links
Pradaxa Side Effect Problems Continue, as New Report Finds Pradaxa Bleeding More Likely to Result in Death, Bernstein Liebhard LLP Reports

New York, NY (PRWEB) January 19, 2013

Pradaxa side effects continue to be reported to the U.S. Food & Drug Administration (FDA), Bernstein Liebhard LLP reports. According to the latest QuarterWatch Report issued by the Institute for Safe Medicine Practices (ISMP), an analysis of hemorrhage cases reported to the FDA during the second quarter of 2012 found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding. The estimate of higher odds for a fatal outcome persisted after adjusting for differences in patient age, gender, and report source, the ISMP said.*

“We continue to hear from Pradaxa patients who experienced frightening episodes of bleeding while using this blood thinner. Considering that there is no readily available antidote for Pradaxa bleeding, we are not surprised by the ISMP’s findings,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The firm is currently offering free Pradaxa lawsuit evaluations to individuals who suffered life-threatening hemorrhaging, allegedly due to Pradaxa.

Pradaxa Lawsuits
Pradaxa, which is used to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation, was approved by the U.S. Food & Drug Administration (FDA) in October 2010. According to a recent report from, regulators in several countries have issued Pradaxa safety alerts since the drug was first brought to market.** Most recently, the FDA released a Drug Safety Communication announcing a new contraindication was being added to the Pradaxa label to warn against its use in patients with mechanical heart valves.***

At least 176 Pradaxa lawsuits have been consolidated in a multidistrict litigation now underway in U.S. District Court, Southern District of Illinois. The complaints allege plaintiffs suffered serious, life-threatening episodes of Pradaxa bleeding, and that Boehringer Ingelheim sold the blood thinner despite knowing it could cause fatal bleeding in some patients. According to court documents, the Pradaxa litigation’s first trial has been scheduled for August 2014. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

Victims of serious Pradaxa bleeding may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. To learn more, please visit the firm’s Pradaxa lawsuit website, or call 1-877-779-1414 to speak with an attorney today.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Approval of Safer Alternative to Pradaxa Delayed by FDA
2. Pradaxa Maker Working on Antidote Amid Pradaxa Bleeding Warnings
3. FDA: Dont Use Pradaxa Blood Thinner in Patients With Artificial Heart Valves
4. Pradaxa Side Effect Warning: Pradaxa Label to Warn Blood-Thinner Shouldn’t be Used in People with Mechanical Heart Valves, Bernstein Liebhard LLP Reports
5. Carey Danis & Lowe Issues an Update on the Pradaxa Multi-District Litigation No. 2385
6. Pradaxa Lawsuits Being Investigated by Bernstein Liebhard LLP, as Next Conference in Federal Pradaxa Litigation Set for January 10th
7. DrugRisk Announces New Pradaxa Health Warning From Australia
8. 176 Pradaxa Lawsuits Now Pending in Federal Litigation, Discovery Well Underway, Bernstein Liebhard LLP Reports
9. Young girls more likely to report side effects after HPV vaccine
10. Preteens More Likely to Report HPV Vaccine Side Effects
11. In children born with severe heart defect, surgical management has little effect on neuro outcomes
Post Your Comments:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology: